⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RNXT News
RenovoRx, Inc. Common Stock
Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
prnewswire.com
GTBP
EVAX
RNXT
EDAP
XNCR
GTBP
EVAX
RNXT
EDAP
XNCR
RenovoRx Expands Scientific Advisory Board with Internationally Renowned Interventional Oncologist, Thierry de Baère, MD, PhD
globenewswire.com
RNXT
RenovoRx’s PanTheR Post-Marketing Registry Study Progresses with First Clinical Procedure and Addition of Two Participating Clinical Sites
globenewswire.com
RNXT